BCL2 and diffuse large B-cell lymphoma: While GPX4 inhbitiors do not meet pharmacokinetics for clinical application yet, the clinically approved drug dimethyl fumarate was found to induce ferroptosis in DLBCL in concert with the BCL2 inhibitor venetoclax (ABT199) [22].